Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02050048 · ClinicalTrials.gov registry record · Phase 2
High Volume Lactated Ringer's Solution and Pancreatitis
A Phase 2 study, sponsored by Endeavor Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT02050048: Clinical Trial Phase 2 study, sponsored by Endeavor Health.
NCT02050048 is a Phase 2 study that was terminated before completion, run by Endeavor Health. The registered enrollment target is 26 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02050048, a Phase 2 study, was terminated before completion, sponsored by Endeavor Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to examine whether giving large amounts of intravenous (IV) fluids will reduce the risk of developing a complication known as post-ERCP pancreatitis (PEP). Pancreatitis is inflammation of the pancreas, and it is the most frequent serious complication of ERCP. Typically, a small amount of IV fluids are given during this procedure (\~ 1 liter). We are testing whether using a larger amount of fluids (2 - 3 liters) will reduce the risk of PEP.
Primary Outcome
Patients will be monitored after procedure to see if they develop abdominal pain. If so, serum amylase and lipase blood draws will be completed at least once every 24 hours following procedure to monitor the development of post-ERCP pancreatitis. If patients do not develop abdominal pain following the procedure, research staff will follow up with the patients 5 days and 29 days after the procedure to evaluate for the development of post-ERCP pancreatitis and other related or unrelated complicati
Interventions
- OTHER Administration of Lactated Ringer's (LR) Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Why NCT02050048 stopped before completion
NCT02050048 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which Administration of Lactated Ringer's (LR) Solution is the first listed.
NCT02050048 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02050048 about?
NCT02050048 is a clinical study titled "High Volume Lactated Ringer's Solution and Pancreatitis". The purpose of this study is to examine whether giving large amounts of intravenous (IV) fluids will reduce the risk of developing a complication known as post-ERCP pancreatitis (PEP). Pancreatitis is inflammation of the pancreas, and it is the most frequent serious complication of ERCP. Typically, ...
What is the current status of trial NCT02050048?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2014-01. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02050048?
The interventions under investigation include: Administration of Lactated Ringer's (LR) Solution (OTHER).
Who is sponsoring clinical trial NCT02050048?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02050048's enrollment target sits among peer trials
26 1708th of 2000 higher than 282 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia